JNJ · News · 20261108N

Icotyde Psoriatic Arthritis Progress

JOHNSON & JOHNSON · 2026-11-08 · Importance 34 · Surprise 42

Johnson & Johnson recently announced promising Phase 3 trial results for ICOTYDE, an oral drug for psoriatic arthritis. The report describes it as a potential first-in-class, once-daily oral treatment that could strengthen the immunology pipeline. The article frames ICOTYDE as a potential contributor to offsetting future revenue losses from older blockbusters such as STELARA, but provides no specific trial efficacy figures.

Key facts